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Deranged liver function tests are encountered in 3% of pregnancies. The potential causes are classiﬁed as
those unique to and those just incidental to pregnancy. Pregnancy-related diseases are the most frequent
causes of liver dysfunction during pregnancy and exhibit a trimester-speciﬁc occurrence during preg-
nancy. Differentiation of liver dysfunction as that related to and just incidental to pregnancy is the key to
management, especially when liver dysfunction is encountered after 28 weeks of pregnancy. It can be
judged from the fact that delivery remains the cornerstone of management of pregnancy-related diseases
except hyperemesis gravidarum. This is an overview of the causes of liver dysfunction during pregnancy;
an update on the underlying mechanisms of their occurrence, especially liver diseases unique to preg-
nancy; and a methodological approach to their diagnosis and management.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Nearly 3% of pregnancies are complicated by liver disorders.
Liver disorders during pregnancy are classiﬁed as those related to
pregnancy and those just coincidental (occurring during pregnancy
or pre-existing). Pregnancy-related disorders are themost common
causes of liver dysfunction during pregnancy and are further
divided into those associated with or without preeclampsia.
Hyperemesis gravidarum (HG), intrahepatic cholestasis of preg-
nancy (ICP), preeclampsia, HELLP (hemolysis, elevated liver en-
zymes, and low platelets) syndrome, and acute fatty liver of
pregnancy (AFLP) are conditions affecting the liver that are unique
to pregnancy. Pregnancy-related liver disorders display character-
istic trimester-speciﬁc clustering in their occurrence, whereas
coincidental liver disorders can occur at any time.Physiological changes during pregnancy
Blood supply to the liver during pregnancy remains unchanged
despite an increase in cardiac output, and so does the liver size.
Telangiectasia and palmar erythema, which are otherwise clinical
markers of liver disease, are seen commonly during pregnancy (dueResidential Complex, Basni,
har).
bstetrics & Gynecology. Publishedto a hyperestrogenic state). Decreased gall bladder motility with
increased secretion of cholesterol in the second and third tri-
mesters increases the lithogeneicity of bile.
Liver function tests
Serum alanine transaminase (ALT), aspartate transaminase
(AST), gamma-glutamyl transpeptidase, and bilirubin values
remain unchanged during pregnancy; however, their ranges are
changed, with a reduction in the upper end. This is a consequence
of hemodilution occurring during pregnancy. Alkaline phosphatase
is elevated (up to 300%) but is placental in origin. There is an in-
crease in the hepatic synthesis of coagulation factors VII, VIII, and X
and ﬁbrinogen; however, the ranges for prothrombin time and
activated partial thromboplastin time remain unchanged. It is
believed that prolonged prothrombin time is a good earlymarker of
hepatic synthetic dysfunction. Serum albumin concentrations fall
due to hemodilution.
Hyperemesis gravidarum
HG complicates 0.3e2.0% of pregnancies [1,2]. It is characterized
by intractable vomiting in the ﬁrst trimester (typically 4e10
weeks), leading to dehydration, ketosis, and weight loss of 5%,
necessitating hospitalization. HG is not a liver disease in the strict
sense, but it leads to liver dysfunction in 50% of cases. The mech-
anism of liver involvement in HG is multifactorial and not wellby Elsevier Taiwan LLC. All rights reserved.
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This form of gestational transient thyrotoxicosis is not associated
with any unfavorable pregnancy outcome and does not require any
treatment. HG-associated liver dysfunction should be a diagnosis of
exclusion. A woman presenting with liver dysfunction with or
without HG in the ﬁrst trimester must be carefully investigated to
rule out other causes of liver dysfunction (viral hepatitis and drug-
induced liver injury).
Liver function abnormalities
There are mild to up to 20-fold elevations in AST and ALT
(ALT > AST) and rarely mild jaundice. Liver function abnormalities
and other biochemical abnormalities resolve upon resolution of
vomiting. Other biochemical abnormalities seen are hypokalemia,
hyponatremia, and ketonuria.
Management
Management of HG is supportive and includes intravenous
rehydration with a short period of fasting, followed by reintro-
duction of a diet rich in carbohydrates and low in fat. Antiemetics
such as dopamine antagonists (metoclopramide and domper-
idone), phenothiazines (chlorpromazine and prochlorperazine), or
antihistamine H1 receptor antagonists (cyclizine and prom-
ethazine) are used safely during pregnancy [3]. Thiamine supple-
mentation is given with dextrose infusion, particularly in women
with a history of prolonged (over weeks) vomiting, to prevent
Wernicke's encephalopathy.
Intrahepatic cholestasis of pregnancy
ICP is the most frequent cause of cholestasis during pregnancy.
However, occurrence of cholestasis during pregnancy does not al-
ways imply the clinical diagnosis of ICP, because pregnancy itself is
a cholestatic condition and chronic liver diseases may be unmasked
for the ﬁrst time during pregnancy with clinical presentation of
cholestasis. Differentiation of ICP from other chronic liver diseases
is important, because both maternal and fetal prognosis vary. ICP
prevalence varies according to countries and populations as there is
considerable genetic inﬂuence. In European countries, 0.5e1.5%
prevalence is seen. South Asia has a higher incidence of ICP.
Clinical presentation
Pruritus is the main and most characteristic symptom. Although
it is generalized, it might be severe in the palms and soles, and
worsens during the night. Pruritus usually develops after 25 weeks,
with 80% of cases occurring after 30 weeks. There are no consti-
tutional symptoms. It usually disappears within the ﬁrst few days
after delivery. Jaundice develops in 10% of cases, 2e4 weeks after
the development of pruritus, and the bilirubin level is usually
<5 mg/dL. Intense cholestasis is associated with steatorrhea, which
is usually subclinical but can cause fat-soluble vitamin deﬁciencies,
most notably deﬁciency of vitamin K. Recent updates point to
lysophosphatidic acid, a potent neuronal activator, and autotaxin,
the enzyme that forms lysophosphatidic acid, as key elements of
the pruritogenic signaling cascade in cholestatic patients suffering
from itching [4].
Liver function tests
Fasting serum bile acid levels of >10 mmol/L is the key diagnostic
test; however, it is not available everywhere. ALT and AST are
usually raised 2e10 times but may be elevated up to 20 times.Transaminases are elevated secondary to increased membrane
permeability of hepatocytes. Gamma-glutamyl transpeptidase
levels are not raised. In fact, raised gamma-glutamyl transpeptidase
activity is considered as a marker of chronic liver disease.
How to make a diagnosis of ICP?
One should be mindful of the following clinical characteristics
when making a diagnosis of ICP:
(1) Typical clinical presentation of pruritus occurring in the
second half of pregnancy; a history of itching during a pre-
vious pregnancy or use of contraceptive pills lends
weightage.
(2) Abnormal liver function tests as described above.
(3) Exclusion of other liver diseases (viral hepatitis and auto-
immune liver disease).
(4) A complete recovery of pruritus and liver function tests soon
after delivery.
Hence, ICP is a presumptive diagnosis until resolution of
symptoms postpartum.
Pathogenesis
ICP is associated with abnormal biliary transport across the
canalicular membrane, the etiology of which is complex and het-
erogeneous. Literature suggests that genetic, hormonal, and exog-
enous factors all play a role in the occurrence of ICP [5].
Genetic
Clustering of ICP cases in families and a high incidence in certain
ethnic groups suggest a genetic predisposition. Identiﬁcation of
mutations and polymorphism of genes involved in hepatobiliary
transport has provided evidence supporting this theory [6,7]. Mu-
tations of the ABCB4 gene, which encodes multidrug resistance
protein 3 (MDR3), as well as those of ABCB11, which encodes the
bile salt export pump, are likely responsible for about 15% of cases
of cholestasis of pregnancy [8e11]. The MDR3 gene product is a
phospholipid ﬂippase that translocates phosphatidylcholine from
the inner to the outer leaﬂet of the canalicular hepatocyte mem-
brane, where it is solubilized by bile acids to form mixed micelles.
Other potential gene products of interest include the Farnesoid X
receptor and transporting ATPase encoded by ATP8B1 [10,12]. There
is, however, no relationship between cholestasis of pregnancy and
human leukocyte antigen type.
Hormonal
The role of estrogens is supported by the facts that ICP is more
common in twin pregnancies (where estrogen levels are higher)
and ICP symptoms are sometimes seen in women given exogenous
estrogens in the form of contraceptive pills. Abnormalities of pro-
gesterone metabolism with an accumulation of sulfate metabolites
saturating the hepatobiliary transport system are also implicated in
ICP. There are case reports of ICP triggered by a prescription of
natural progesterone for preventing preterm delivery in the third
trimester [13,14].
Exogenous
Had the etiology of ICP been only genetic, all the pregnancies of
predisposed women should have been complicated by ICP. How-
ever, such is not the case, as ICP recurs only in 60e70% of subse-
quent pregnancies. This suggests a role of extraneous factors in
inﬂuencing the occurrence of ICP in genetically predisposed
women. Other facts that support the role of exogenous factors are
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countries, and a decreasing prevalence of ICP in Chile, possibly due
to a fall in the mean plasma selenium levels [15]. Irrespective of the
inciting agent(s), there is incomplete clearance of bile acids with
subsequent accumulation in plasma.
Prognosis for mother and fetus
ICP has a benignprognosis formothers. Recovery is complete, and
no serious short- or long-term maternal morbidity is seen with ICP.
However, a recent longitudinal retrospective population-based
cohort study has shown an association of ICP with several liver dis-
eases [16]. In addition, 60e70% of affected individuals develop
cholestasis during subsequent pregnancies. As far as the fetal
outcome is concerned, older literature suggested an adverse peri-
natal outcome in women with ICP due to prematurity, chronic
placental insufﬁciency, anoxia, meconium passage, and sudden in-
trauterine fetal death (IUFD). However, data collected in the past 2
decades is ambiguous concerning excessive perinatal mortality and
whether fetal surveillance strategies prevent this increased risk. To
illustrate the point, a review of few studies is presented here. In a
study by Glantz and colleagues [17], perinatal mortality was
increased butwas seen only in thosewomenwho had severe disease,
characterized by very high total serum bile acid levels. By contrast,
Sheiner and coworkers [18] did not ﬁnd any difference in the peri-
natal outcomes when they compared 376 pregnancies with ICP with
their general obstetric population. Lee and associates [19] described
two cases of sudden fetal death despite close fetal surveillance. Two
more studies did not report any excess risk of term fetal demise
[20,21]. However, almost all these studies reported a very high rate of
labor induction to avoid stillbirths. One of the studies reported novel
associations of ICP with preeclampsia and gestational diabetes. It has
been suggested that bile acidsmay cause fetal death by cardiac arrest
after entering cardiomyocytes in enormous amounts [22]. The risk of
sudden IUFD is currently 1% in developed countries and is rarely seen
before the last month of pregnancy.
Medical and obstetrical management
Management of ICP is twofold: symptomatic therapy for the
mother, and close surveillance and early delivery of the fetus.
Symptomatic management of mother
Ursodeoxycholic acid in doses of 10e15 mg/kg/d is the treat-
ment of choice for ICP at present. It provides relief against pruritus,
improves liver function tests, and appears to be safe during preg-
nancy. At the molecular level, it offers cytoprotection against hep-
atotoxic effects of hydrophobic bile acids, improves hepatobiliary
bile acid transport, and decreases plasma bile acid. Hydroxyzine
(25 mg/d) or an aqueous cream with 1% menthol may be used to
alleviate pruritus. Treatment with bile-acid binders such as chole-
styramine and guar gum may also relieve symptoms, however, it is
important to keep in mind that therapy with these agents worsens
steatorrhea and resultant fat-soluble vitamin deﬁciencies. Admin-
istration of S-adenosyl methionine to patients with cholestasis of
pregnancy has had mixed therapeutic results; use in combination
with ursodeoxycholic acid may increase its beneﬁt. As in other
cholestatic syndromes, no treatment is always and completely
effective in persons with cholestasis of pregnancy, with the usual
exception of delivery.
Management for fetus
Close fetal monitoring and early delivery (preferably 37 weeks,
but no later than 38 weeks) remains the cornerstone of obstetric
management, although the evidence is lacking. An even earlierdelivery is advocated when cholestasis is severe [23]. However,
sudden IUFD cannot be avoided totally even with this approach.
Preeclampsia/hypertension-related liver diseases and
pregnancy
Preeclampsia/eclampsia
Preeclampsia is deﬁned as hypertension and proteinuria after 20
weeks of pregnancy and within 48 hours of delivery. It complicates
10% of pregnancies. It is a multisystem disorder, and the liver is
involved in 20e30% of preeclampsia cases. It is the most common
cause of liver dysfunction and hepatic tenderness in pregnancy
[24]. Liver involvement is secondary to vasospasm of the hepatic
vascular bed. Aminotransferase levels are usually elevatedmildly to
up to 10 times normal values; however, they might occasionally be
elevated up to 20 times normal values. Jaundice occurs only occa-
sionally (5%) and the bilirubin level is usually <5 mg/dL. Liver
involvement in preeclampsia is an indicator of the severity of
preeclampsia, and no speciﬁc therapy for liver involvement is
required.
HELLP syndrome
HELLP is a severe variant of preeclampsia and complicates
around 2e12% of preeclampsia cases [25]. It is deﬁned by the
presence of: (1) hemolysis; (2) elevated liver enzymes; and (3) low
platelet counts.
Etiology
There are endothelial injury and ﬁbrin deposition in blood
vessels, leading to microangiopathic hemolytic anemia (schisto-
cytes and burr cells on smear) with platelet activation and con-
sumption. Consequently, small to diffuse areas of hemorrhage and
necrosis develop from Zone 1 to involve the whole lobule. This may
occasionally lead to large hematomas, capsular tears, and intra-
peritoneal hemorrhage.
Clinical features
The majority of patients present in the third trimester (28e36
weeks of gestation), however, 30% of cases occur in the postpartum
period. There is no typical presenting sign or symptom that dis-
tinguishes HELLP from preeclampsia. Midepigastric or right upper
quadrant abdominal pain is the commonest feature. Other symp-
toms are nausea, vomiting, malaise, and headache. Jaundice is
present in approximately 5% of cases [26].
Differential diagnosis
Occasionally, HELLP syndrome must be distinguished from
other conditions, especially AFLP (with which it has a signiﬁcant
overlap) [27], or from the rare conditions of thrombotic thrombo-
cytopenic purpura, hemolytic uremic syndrome, or anti-
phospholipid syndrome (especially in the presence of hepatic
infarction). Acute fatty liver is usually associated with signs of more
signiﬁcant liver disease and possibly liver failure, albeit with lower
serum aminotransferase levels, and is not necessarily associated
with thrombocytopenia.
Management
The cornerstone of management in HELLP syndrome is prompt
delivery [28]. Women must be hospitalized and managed in high-
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and biochemical investigations, liver imaging with computed to-
mography scan (limited views) or magnetic resonance imaging
should be done to identify hepatic complications of infarction, liver
parenchymal hemorrhage, or subcapsular hematoma, because ul-
trasound is not a reliable tool for identifying these complications.
Hypertension must be controlled aggressively, and blood or blood
products should be used, if required, to improve anemia or coag-
ulation disorders. After initial optimization, delivery must imme-
diately be effected in pregnancies: (1) at or beyond 34 weeks of
gestation or with evidence of; (2) multiorgan dysfunction; (3)
disseminated intravascular coagulation (DIC); (4) renal failure; (5)
abruption placentae; or (6) fetal distress.
Management of HELLP syndrome remote from term with fetal
lung immaturity and stable maternal condition is controversial
[27,28]. We believe that delivery must immediately be effected
after temporizing management and corticosteroid therapy for
24e48 hours in such cases. A longer conservative therapy in such
cases will lead to deterioration of maternal disease within 1e10
days with a high risk of fetal loss.
Hepatic complications of HELLP syndrome/preeclampsia
Major hepatic complications of HELLP syndrome are rare (5% of
cases) [29] and are as follows:
(1) Intraparenchymal hemorrhage
(2) Liver infarction
(3) Subcapsular hematoma
(4) Hepatic rupture
(5) Hepatic failureHepatic infarction
Right upper quadrant pain and fever with marked elevation in
serum aminotransferases are characteristics of liver infarction. It
can be conﬁrmed on computed tomography scan. Patients may
have an underlying procoagulant state such as antiphospholipid
antibody syndrome. It is less frequent than subcapsular hematoma
formation.
Hepatic parenchymal hemorrhage and subcapsular hematoma
These complications correlate with the severity of thrombocy-
topenia. Presenting features are severe upper abdominal pain with
pyrexia and anemia. Serum aminotransferase values are in the
range of thousands. Hepatic intraparenchymal hemorrhage and
contained hematomas in hemodynamically stable patients are
managed conservatively with aggressive correction of coagulop-
athy and anemia. However, there is a possibility of rapid expansion
of hematoma and liver rupture; hence, intensive hemodynamic
monitoring should be done. Moreover, there should be immediate
availability of large volumes of blood/blood products for trans-
fusion and surgical intervention, should the need arise. Exogenous
trauma such as abdominal palpation, convulsions, emesis, and
unnecessary transportation must be avoided. Management of he-
modynamically unstable patients is aggressive resuscitation with
immediate laparotomy.
Liver rupture
It is a life-threatening complication and is usually preceded by
intraparenchymal hemorrhage progressing to contained subcapsular
hemorrhage in the right lobe in patients with severethrombocytopenia. Maternal mortality is 50%, and survival depends
on rapid aggressive supportive care and immediate laparotomy. The
most effective surgical management is evacuation of hematomawith
pressure packing and drainage, along with hepatic artery ligation.
Acute fatty liver of pregnancy
AFLP is a rare (1 in 20,000 deliveries) and catastrophic disease
with high maternal and fetal mortality. It is the most common
cause of acute liver failure during pregnancy and is also known as
acute yellow atrophy or acute fatty metamorphosis. As a rule, AFLP is
a disease of the third trimester. Abnormalities in fatty acid oxida-
tion lead to microvesicular fatty inﬁltration of hepatocytes, result-
ing in widespread damage.
Etiology
Despite increasing understanding of the disease, much remains
to be learned. The data are conﬂicting, and our interpretation is
incomplete yet intriguing. The principal abnormality found in some,
if not all, cases of AFLP is a defect in the mitochondrial fatty acid
oxidation in the mother and her fetus. Two enzymes involved in
mitochondrial fatty acid oxidation, whose mutations are closely
linked with AFLP, are mitochondrial trifunctional protein and its
alpha subunit long-chain 3-hydroxyacyl-CoA-dehydrogenase
(LCHAD). The most common mutations are the G1528C and E474Q
of the gene on chromosome 2 that code for LCHAD. There are other
mutations for medium chain dehydrogenase as well as carnitine
palmitoyltransferase 1 deﬁciency [30,31]. Our current understand-
ing from a number of studies is that when a mother is heterozygous
for LCHAD deﬁciency and carries a fetus that is homozygous or
compound heterozygous for LCHADmutation, then there is reduced
maternal capacity to oxidize long-chain fatty acids coupled with
placental and fetal deﬁciency to do so. This leads to abnormal
accumulation of long-chain fatty acid metabolites in maternal cir-
culation. Thesemetabolites then get deposited in hepatocytes (fatty
inﬁltration) and cause hepatotoxicity. Apart from AFLP, fatty acid
oxidation defects in mother and fetus have also been reported with
HELLP syndrome. Despite this controversial association, leading
authorities have concluded that given the sufﬁciently disparate
clinical, biochemical, and histopathological ﬁndings, HELLP syn-
drome and AFLP are different clinical syndromes [32].
Clinical features
Unlike HELLP, the majority of womenwith AFLP are nulliparous.
Clinical presentation is variable; however, the most frequent
symptoms are anorexia for a couple of weeks, nausea, vomiting,
right upper abdominal pain, and headache. The women are ill
looking and jaundiced, and may be hypertensive and edematous.
Patients may have ascites (partly due to portal hypertension), and
the liver is small or normal in size. In severe forms, patients may
demonstrate hepatic encephalopathy with or without coma. Up to
half of patients with AFLP will have hypertension and/or protein-
uria (preeclampsia), and hence classiﬁed as those with
preeclampsia/hypertension-associated liver disease in pregnancy
[33]. Polyuria and polydypsia are pathognomic symptoms in the
setting of liver disease in pregnancy; however, these are present in
only 5% of cases. Affected individuals have a greater-than-expected
number of male fetuses (2.7:1) [34].
Laboratory abnormalities
AST and ALT are elevated up to 300e500 times usually, but not
as high as in viral hepatitis. Hyperbilirubinemia is common but
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and ﬁbrinogen levels are decreased (due to hepatic synthetic defect
and DIC). Variable degrees of hypoalbuminemia and hypo-
cholesterolemia are seen. A clinical vignette is that low platelets in
late pregnancy should prompt one to perform liver function tests to
rule out AFLP.
Hematological abnormalities
There is hemolysis evidenced by leukocytosis, nucleated red
cells, thrombocytopenia, and raised lactate dehydrogenase (LDH).
Peripheral blood smear demonstrates echinocytosis with normo-
cytic normochromic anemia, however, hematocrit is usually within
normal limits due to hemoconcentration. Hypoglycemia is char-
acteristic and is a poor prognostic feature. Other biochemical ab-
normalities are metabolic acidosis, renal dysfunction, high
ammonia, and biochemical pancreatitis.
Diagnosis
Microvesicular steatosis on liver biopsy is diagnostic, but it is
rarely necessary. Moreover, coagulopathy precludes liver biopsy in
most of the situations. Therefore, in the majority of cases, a pre-
sumptive diagnosis of AFLP is made based on clinical and laboratory
ﬁndings. Swansea diagnostic criteria have been proposed as an
alternative to liver biopsy (Table 1) [35]. The histologic hallmark of
AFLP is microvesicular fatty inﬁltration of the liver that is most
prominent in hepatocytes surrounding the central veins (Zone 3)
and spares those surrounding portal areas.
Differential diagnosis
Hypertension, proteinuria, and other clinical and laboratory
features have been observed to overlap between AFLP and HELLP
syndrome. However, compared with HELLP syndrome, patients
with AFLP are more likely to have hepatic failure with coagulop-
athy, hypoglycemia, encephalopathy, and renal failure (Table 2).
Viral hepatitis must be ruled out by serological testing in every case.
Management
Prompt delivery with intensive supportive care is the primary
therapy. There are no reports of recovery before delivery in litera-
ture. Management begins with hospitalization and initial stabili-
zation (correction of coagulation and other abnormalities). Delivery
should be effected promptly, which is usually by cesarean sectionTable 1
Swansea diagnostic criteria for diagnosis of acute fatty liver of pregnancy.
Six or more of the following features in the absence of another explanation:
 Vomiting
 Abdominal pain
 Polydypsia/polyuria
 Encephalopathy
 High bilirubin (>14 mmol/L)
 Hypoglycemia (<4 mmol/L)
 High uric acid (>340 mmol/L)
 Leucocytosis (>11  106/L)
 Ascites or bright liver on ultrasound
 High AST/ALT (>42 IU/L)
 High ammonia (>47 mmol/L)
 Renal impairment (creatinine >150 mmol/L)
 Coagulopathy (PT >14 s or aPTT >34 s)
 Microvesicular steatosis on liver biopsy
ALT ¼ alanine transaminase; aPTT ¼ activated partial thromboplastin time;
AST ¼ aspartate transaminase; PT ¼ prothrombin time.after correction of coagulation disorders. Although a vaginal de-
livery would reduce the chances of major peritoneal bleeding, it
should be tried only if it seems possible in <24 hours with an in-
ternational normalized ratio of <1.5 and a platelet count of
>50,000. Transfusions with whole blood or packed red cells along
with fresh frozen plasma, cryoprecipitate, and platelets are usually
required. A hepatologist should be involved early on. Prophylactic
antibiotics are recommended to prevent uterine infections. Blood
sugar levels must be monitored closely.
Most patients recover within 1e4 weeks (although a phase of
cholestasis may persist longer). During postpartum recovery, a
quarter of patients may develop transient diabetes insipidus and
nearly 20%maydevelop acute pancreatitis. Recovery is completewith
no signs of chronic liver disease. With early delivery and advances in
supportive care, maternal mortality is now 7e18%. Infections and
bleeding remain the most life-threatening complications. Liver
transplantation has a limited role in patients with fulminant hepatic
encephalopathy and those who fail to recover after delivery.
Recurrence and screening
Most womenwould not become pregnant again either by choice
or due to necessity of hysterectomy to control post partum hem-
orrhage (PPH). There is 20e70% chance of recurrence in the case of
repeat pregnancy. All womenwith AFLP and their offspringmust be
screened for abnormalities of fatty acid oxidation.
Pre-existing liver diseases
Cirrhosis and pregnancy
Most women with advanced cirrhosis will not conceive, as they
are amenorrheic and infertile due to hypothalamic dysfunction
[36,37]. Nonetheless, pregnancy is achieved by many, and even
successfully completed in those with well-compensated disease
and mild portal hypertension. Fetal loss, and maternal morbidity
and mortality remain high in pregnant women with cirrhosis, and
hence such cases should be managed by obstetricians focusing on
high-risk pregnancy and hepatologists. The most common
complication is variceal bleeding seen in a third to half of affected
women [38]. Variceal bleeding usually occurs from varices near the
gastroesophageal junction, especially during the second trimester
and the second stage of labor, due to worsening of portal hyper-
tension [24]. All women with cirrhosis and portal hypertension
planning to conceive should undergo variceal screening and
banding of varices before pregnancy. Additionally, those with no
varices before pregnancy should undergo endoscopy during the
second trimester, and if found to have varices, they should be
managed with beta-blocker therapy. Acute variceal bleeding is
managed with endoscopic band ligation. Sclerotherapy is avoided,
because there is a potential risk of injecting sclerotherapeutic
chemicals. If endoscopy is not available, then balloon temponade
can be lifesaving. Vasopressin is contraindicated during pregnancy.
Other complications are hepatic decompensation with worsening
synthetic liver functions, jaundice, thrombocytopenia, ascites, and,
rarely, rupture of splenic aneurysms. The best route of delivery is
unknown. However, those with known large varices are best
delivered by cesarean section. In the absence of large varices,
assisted vaginal delivery with shortening of second stage can be
accomplished.
Acute viral hepatitis
Viral hepatitis due to hepatitis A, B, C, D, and E, and herpes
simplex, cytomegalovirus, and EpsteineBarr virus accounts for40%
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[39]. Most cases of acute viral hepatitis are subclinical and anicteric.
Clinical presentation is similar in all with nausea, vomiting, head-
ache, malaise, and subsequent development of jaundice. Viruses
may not be hepatotoxic, however, the immunological response
causes the hepatocellular necrosis. All cases of hepatitis A will
recover completely, and so will most of the cases of hepatitis B.
However, complete clinical and biochemical recovery will be seen
only in a small proportion of cases of hepatitis C.
Hepatitis A
The course of hepatitis A in pregnancy is similar to that seen in
the nonpregnant state. Symptoms are usually mild and last for <2
months. Early on immunoglobulin M antihepatitis A virus anti-
bodies are detected, and immunoglobulin G antihepatitis A virus
antibodies are seen in convalescence. Hepatitis A in the third
trimester is associated with an increased risk of prematurity [40].
Treatment remains supportive, with a balanced diet and dimin-
ished physical activity. Fetal transmission is negligible, and the vi-
rus is not teratogenic. Centers for Disease Control (CDC)
recommends a postexposure (close contact or sexual contact)
immunoprophylaxis in pregnant womenwith a 0.02-mL/kg dose of
immune globulin [41]. Literature reports high maternal and peri-
natal mortality rates in resource-poor countries. All cases have a
complete recovery, and there is no chronic stage of hepatitis A.
Hepatitis B
This virus is found worldwide with endemic presence in Africa,
Southeast Asia, China, and the Middle East. Fifty percent of cases
are asymptomatic, and when symptoms are present, they are
usually mild. Serological course during pregnancy is the same as
that seen outside pregnancy, with hepatitis B surface antigen being
the ﬁrst serological marker detected. Core antigen (HBc) is not
detected in serum; however, anti-HBc antibodies are detectable
next. Hepatitis Be (HBe) antigen is a marker of viral replication.
Complete resolution is seen in 90% of cases within 3e4 months,
and this is evidenced by the disappearance of hepatitis B surface
(HBs) antigen and the appearance of anti-HBs antibodies. Ten
percent will remain chronically infected. One of the risk factors for
chronic disease is the age at the time of infectiond>90% in
newborn, 50% in young children, and <10% in immunocompetent
adults. Literature suggests a moderately increased risk of preterm
in hepatitis B virus (HBV)-positive pregnant women [42]. Vertical
transmission and measures to reduce vertical transmission are
discussed separately.
Hepatitis C
Acute infection is usually asymptomatic or mild. Most of the
cases are anicteric. Hepatitis C RNA testing is considered a “gold
standard” for the diagnosis of hepatitis C virus. Recent literature
suggests an excess risk for fetuses with increased incidences of low
birth weight, preterm delivery, and admissions to neonatal inten-
sive care units. Treatment for acute infection during pregnancy is
supportive. Of the patients, 90% will remain chronically infected
with hepatitis C virus.
Hepatitis E
This is probably the most common cause of acute hepatitis [43].
Hepatitis E is endemic in India, and pregnant women are more
vulnerable to hepatitis E than hepatitis A, B, or C. Hepatitis E tends
to run a severe course in pregnancy, especially in India, withincreased propensity to develop fulminant hepatic failure in the
third trimester [44,45]. Maternal and fetal mortality secondary to
fulminant hepatic failure is very high (41e54% and 69%, respec-
tively) [46]. High viral loads and very high cytokine secretion might
be responsible for fulminant hepatic failure during pregnancy.
Importantly, delivery does not change the outcome, and manage-
ment remains supportivewith the patient being ideallymanaged in
an intensive care unit.
Herpes simplex virus hepatitis
Herpes simplex viral hepatitis is a rare entity; however, preg-
nant women are more susceptible than the general population. The
course during pregnancy is usually severe and fulminant, with high
maternal mortality. Herpes simplex viral hepatitis leads to “anic-
teric hepatitis” with normal levels of bilirubin in the presence of
severe derangements in liver function tests. Mucocutaneous
manifestation of herpes simplex infection occurs in only 50% of
cases [45]. A high degree of suspicion would be lifesaving, as
treatment with intravenous acyclovir is effective.
Viral hepatitis and vertical transmission
The primary concern with chronic hepatitis B infection in
pregnancy is the possibility of vertical transmission. In fact, 35e50%
of cases of chronic HBV infections in endemic areas are due to
vertical transmission. Foremost in the strategy to reduce vertical
transmission of HBV infection is routine screening of pregnant
women for HBV at the initial booking visit. Women who are
without immune antibodies and display a high-risk behavior
(intravenous drug abuse andmultiple sex partners) are at increased
risk of acquiring hepatitis B during pregnancy and can be given
hepatitis vaccine with little risk to the fetus. The key factors in
vertical transmission are presence of HBe antigen (suggesting
active viral replication), anti-HBe antibodies, and the viral load.
Vertical transmission is maximum in the presence of HBe antigen
and a high viral load (50e80%), lower with anti-HBe (25%), and
lowest in carriers (5%) [23]. Vertical transmission can be reduced
signiﬁcantly (up to 95%) by passiveeactive immunoprophylaxis of
babies with hyperimmune B immunoglobulin within 12 hours of
birth and hepatitis B vaccination within ﬁrst 6 months. Cesarean
section does not reduce the transmission rates.
Use of antiviral therapy during pregnancy to reduce the vertical
transmission of hepatitis B is a controversial issue, and no guide-
lines exist at present. Some people advocate the use of lamivudine
(pregnancy category C drug) monotherapy after 32 weeks of
pregnancy, when viral load is in excess of 106 viral copies/mL [46].
This can be considered in womenwho have infected their child in a
previous pregnancy. However, there are concerns of viral resistance
with lamivudine monotherapy. Reports of two other antiviral
medications, telbivudine and tenofovir, in pregnancy are also
encouraging [47e49]. The use of hyperimmune B immunoglobulin
antenatally in women at the highest risk of vertical transmission
also seems to be effective in decreasing transmission rates [50].
HBV infection is not considered a contraindication for breast
feeding by the American Academy of Pediatrics.
Vertical transmission with maternal hepatitis C infection is very
low. However, maternal coinfection with human immunodeﬁ-
ciency virus, and fetal exposure to a large volume of maternal blood
or secretion during delivery in the presence of a high viral load
increases the rates of vertical transmission [51e53]. Vertical
transmission of hepatitis C is not prevented by treatment of the
infant with immunoglobulin. Women are not treated with inter-
feron and ribavirin during pregnancy because of teratogenic po-
tential of ribavirin in animals.
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curs only with high viral loads (acute phase) during delivery.
Hence, newborns of mothers contracting hepatitis A in the third
trimester should be administered immune globulin within 48
hours of birth.Gall bladder disease and pregnancy
Pregnancy favors gall stone formation for the following reasons.
Cholesterol secretion increases in the second and third trimesters
compared with other constituents of the bile, and hence the bile
gets supersaturated with cholesterol. Second, gall bladder volumes
are higher during pregnancy due to a decreased rate and volume of
emptying. Thus, large residual volumes of supersaturated bile
eventually lead to stone formation in up to 10% of pregnant women.
Interestingly, despite a high prevalence of gall stone formation
during pregnancy, women usually become symptomatic following
the delivery. In fact, symptomatic gall stone disease remains the
number one nonobstetric reason for hospital admission in the year
following delivery.
The principal clinical presentations of gall stone disease, in order
of frequency during pregnancy, are acute biliary colic, acute
cholecystitis, and gall stone pancreatitis (rare). Initial management
of uncomplicated acute biliary colic and cholecystitis during preg-
nancy is supportive, with bed rest, intravenous hydration, antimi-
crobials, and analgesics. However, cholecystectomy is indicated for
intractable biliary colic, severe acute cholecystitis not responding to
conservative management, and acute gallstone pancreatitis. In the
past, most favored medical therapy. However, due to 50% recur-
rence of biliary colic before delivery, operative and endoscopic in-
terventions are increasingly being favored. If cholecystitis recurs
during late pregnancy, then preterm labor is likely and surgery is
technically more difﬁcult due to enlarged uterus. It has been re-
ported that those managed conservatively had more pain, more
emergency visits, and higher rates of hospitalization and cesarean
section [54]. It is recommended that those presenting with symp-
tomatic gall stone disease in the ﬁrst and second trimesters should
undergo cholecystectomy during the second trimester. Surgery is
avoided in the ﬁrst trimester due to risk of abortionwith anesthesia
and in the third trimester due to the risk of preterm labor. Extra-
hepatic ductal stones are best managed by endoscopic retrograde
cholangiopancreatography, sphincterotomy, and stone extraction
under antibiotic coverage.Table 2
Key learning points.
 Three percent of the pregnancies are affected by liver diseases.
 Severe liver disease in pregnancy is rare.
 Liver diseases during pregnancy can be divided into those related
to pregnancy and those just incidental to pregnancy, and this distinction
is important as the cornerstone of management in most pregnancy-related
diseases (except hyperemesis gravidarum) is termination of pregnancy.
 Pregnancy-related liver diseases are most frequent causes of liver
dysfunction during pregnancy.
 Pregnancy-related liver diseases have characteristic timings in relation
to the trimesters of pregnancy. Hyperemesis gravidarum occurs in the ﬁrst
trimester, intrahepatic cholestasis in late second and third trimesters, and
HELLP, eclampsia, and AFLP mainly occur in the third trimester.
AFLP ¼ acute fatty liver of pregnancy; HELLP ¼ hemolysis, elevated liver enzymes,
and low platelets.Conﬂicts of interest
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